EUVIMEDEUVIMED entdecken
Open Access

A 3D lymphatics-on-a-chip reveals matrix stiffness dependent VEGFR-2 and VEGFR-3 contributions to lymphangiogenesis

Lauren C Richardson, Issahy Cano, Anna M Kolarzyk, Esak Lee

Acta Biomaterialia · 2026-11 · 225 · 617-631

DOI: 10.1016/j.actbio.2026.10.013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Biomaterialia, 2026-11. Verfasst von Lauren C Richardson und 3 weiteren Autor:innen. Beteiligte Einrichtung: Nancy E. and Peter C. Meinig School of Biomedical Engineering, Cornell University, Ithaca, New York, USA. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor Receptor-3, Vascular Endothelial Growth Factor Receptor-2, Lymphangiogenesis, Lymphatic Vessels. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NHLBI NIH HHS, NSF.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The lymphatic system regulates fluid homeostasis and host immunity by draining interstitial fluid and immune cells and transporting them to the lymph nodes. Lymphatic capillaries, essential for capturing interstitial material, undergo lymphangiogenesis to form new lymphatic vessels from existing ones. However, the roles of the vascular endothelial growth factor (VEGF) family and their receptors in lymphangiogenesis under varying matrix stiffness conditions remain unclear. We examine lymphangiogenesis in response to VEGF-A, VEGF-C, and VEGF-C156S across different matrix stiffnesses and evaluate the effects of VEGFR-3 and VEGFR-2 inhibition in a three-dimensional (3D) lymphatics-on-a-chip model. In the model, VEGF-C induced the greatest lymphangiogenesis across all tissue stiffnesses. VEGF-A driven lymphangiogenesis was also notable in compliant and stiff matrices. VEGF-C156S-induced lymphangiogenesis was weaker than that in VEGF-A and VEGF-C conditions. Given that VEGF-C promoted the greatest sprouting across all matrix conditions and could interact with both VEGFR-3 and VEGFR-2, we examined VEGF-C driven lymphangiogenesis under VEGFR-3 and VEGFR-2 inhibition. In a soft matrix, VEGF-C driven lymphangiogenesis was significantly blocked by the VEGFR-3 inhibitor but less extensively blocked by the VEGFR-2 inhibitor; in a stiff matrix, either the VEGFR-3 or VEGFR-2 inhibitors significantly blocked lymphangiogenesis, indicating that lymphangiogenic VEGFR-3 pathways mediate VEGF-C induced lymphangiogenesis the most in a soft matrix. VEGFR-2 can similarly contribute to lymphangiogenesis in a stiff matrix, showing VEGF-C mediated sprouting loses stiffness resilience under VEGFR-2 inhibition. Ultimately, VEGF-C/VEGFR-3 signaling has a greater impact on lymphangiogenesis in a compliant matrix, but VEGF-C/VEGFR-2 signaling mediates stiffness-resistant lymphangiogenesis in a stiff matrix. STATEMENT OF SIGNIFICANCE: The lymphatic system preserves fluid homeostasis by draining interstitial fluid. Lymphatic capillaries form new vessels through lymphangiogenesis across tissues spanning soft to stiff environments, yet how VEGF signaling functions under varying matrix stiffness remains unclear. Using a 3D lymphatics-on-a-chip model, we investigated lymphangiogenesis induced by VEGF-A, VEGF-C, and VEGF-C156S and assessed VEGFR-3 and VEGFR-2 inhibition. VEGF-C produced the strongest sprouting across all stiffness conditions; VEGF-A elicited weaker responses, and VEGF-C156S was effective only in soft matrices. In compliant matrices, VEGF-C-driven sprouting depended primarily on VEGFR-3. In stiff matrices, inhibition of either VEGFR-3 or VEGFR-2 significantly reduced lymphangiogenesis, revealing stiffness-dependent receptor contributions to VEGF-C-mediated sprouting, suggesting distinct therapeutic strategies for varying ECM stiffness in different organs and diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vascular Endothelial Growth Factor Receptor-3Vascular Endothelial Growth Factor Receptor-2LymphangiogenesisLymphatic VesselsLab-On-A-Chip DevicesExtracellular MatrixAnimalsVascular Endothelial Growth Factor CVascular Endothelial Growth Factor AMicrophysiological SystemsHumans

Stichwörter der Autor:innen

ECM stiffnessLymphangiogenesisLymphatics-on-a-chipVEGFR-2VEGFR-3

Substanzen

Vascular Endothelial Growth Factor Receptor-3Vascular Endothelial Growth Factor Receptor-2Vascular Endothelial Growth Factor CVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Nancy E. and Peter C. Meinig School of Biomedical Engineering, Cornell University, Ithaca, New York, USA.
  • Department of Biomedical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York, USA.
  • Nancy E. and Peter C. Meinig School of Biomedical Engineering, Cornell University, Ithaca, New York, USA. Electronic address: el767@cornell.edu.

Förderung

  • NCI NIH HHS
  • NHLBI NIH HHS
  • NSF
  • National Science Foundation
  • NIH

Zitieren

APA

Richardson, L. C., Cano, I., Kolarzyk, A. M., & Lee, E. (2026). A 3D lymphatics-on-a-chip reveals matrix stiffness dependent VEGFR-2 and VEGFR-3 contributions to lymphangiogenesis. Acta Biomaterialia, 225, 617-631. https://doi.org/10.1016/j.actbio.2026.10.013

Vancouver

Richardson LC, Cano I, Kolarzyk AM, Lee E. A 3D lymphatics-on-a-chip reveals matrix stiffness dependent VEGFR-2 and VEGFR-3 contributions to lymphangiogenesis. Acta Biomaterialia. 2026;225:617-631. doi:10.1016/j.actbio.2026.10.013

BibTeX
@article{Richardson2026,
  author = {Richardson, Lauren C and Cano, Issahy and Kolarzyk, Anna M and Lee, Esak},
  title = {A 3D lymphatics-on-a-chip reveals matrix stiffness dependent VEGFR-2 and VEGFR-3 contributions to lymphangiogenesis},
  journal = {Acta Biomaterialia},
  year = {2026},
  volume = {225},
  pages = {617--631},
  doi = {10.1016/j.actbio.2026.10.013}
}
Kostenlos starten →